Celgene Corporation (CELG) : Premier Asset Managment reduced its stake in Celgene Corporation by 6.05% during the most recent quarter end. The investment management company now holds a total of 123,875 shares of Celgene Corporation which is valued at $12,465,541 after selling 7,980 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Celgene Corporation makes up approximately 3.18% of Premier Asset Managment’s portfolio.
Other Hedge Funds, Including , Toth Financial Advisory Corp added CELG to its portfolio by purchasing 6,130 company shares during the most recent quarter which is valued at $616,862. Celgene Corporation makes up approx 0.19% of Toth Financial Advisory Corp’s portfolio.Genesee Valley Trust Co reduced its stake in CELG by selling 113 shares or 0.9% in the most recent quarter. The Hedge Fund company now holds 12,407 shares of CELG which is valued at $1,261,047. Celgene Corporation makes up approx 0.82% of Genesee Valley Trust Co’s portfolio.Morgens Waterfall Vintiadis Co Inc reduced its stake in CELG by selling 26,000 shares or 46.43% in the most recent quarter. The Hedge Fund company now holds 30,000 shares of CELG which is valued at $3,049,200. Celgene Corporation makes up approx 2.75% of Morgens Waterfall Vintiadis Co Inc’s portfolio.First National Bank Of Omaha boosted its stake in CELG in the latest quarter, The investment management firm added 31,408 additional shares and now holds a total of 91,255 shares of Celgene Corporation which is valued at $9,275,158. Celgene Corporation makes up approx 0.73% of First National Bank Of Omaha’s portfolio.Cutler Group Lp boosted its stake in CELG in the latest quarter, The investment management firm added 46,166 additional shares and now holds a total of 70,107 shares of Celgene Corporation which is valued at $7,310,057. Celgene Corporation makes up approx 0.45% of Cutler Group Lp’s portfolio.
Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.